Oculis Holding AG (OCS) AI Stock Analysis

Oculis Holding AG is a clinical-stage biopharmaceutical company dedicated to advancing innovative drug candidates tailored for ophthalmic diseases. Headquartered in Zug, Switzerland, the company's lead asset is OCS-01, a topical dexamethasone optireach formulation in Phase 3 clinical trials for diabetic macular edema. It is also advancing OCS-02, a topical biologic candidate in Phase 2b trials for dry eye disease. Additionally, its pipeline includes OCS-05, a disease-modifying neuroprotective agent targeting conditions such as glaucoma, dry age-related macular degeneration, diabetic retinopathy, and acute optic neuritis. The company employs 60 people and focuses on addressing unmet medical needs in global eye care.

Oculis produces minimal commercial revenue as its drug portfolio remains in clinical development. Annual revenue contracted from $993,000 in FY2020 to $686,000 in FY2024, representing a 4-year compound annual growth rate of -8.8%. Revenue fell 22.3% in FY2024, while net loss reached -$85.8M alongside an operating margin of -10671.1%. Research and development expenses grew to $52.1M in FY2024, up from $9.3M in FY2020. For the trailing twelve months ended June 30, 2026, revenue stood at $1.2M with diluted EPS of -$1.74, although quarterly revenue growth grew 18.8% year-over-year in the latest quarter.

As of June 30, 2026, Oculis reported cash and short-term investments of $8,000 and total debt of $2.5M, resulting in net debt of $2.5M. Total assets stood at $250.3M against shareholders' equity of $219.3M. The company maintains a current ratio of 8.35 and a debt-to-equity ratio of 0.01. Free cash flow was -$47.7M in FY2024, reflecting ongoing clinical trial expenditures, while FY2025 capital expenditures were $287,470. Over a five-year period, the company's share count expanded by 87.2%.

With a market capitalization of $449.0M and an enterprise value of $278.6M, Oculis trades at a price-to-sales multiple of 382.8x. This is significantly above the 4.1x price-to-sales median of its US-listed Healthcare peers. Its price-to-book ratio is 2.1x. Over the past year, the stock fell 66.2%, trailing the S&P 500 (SPY) return of 16.8%. Over a five-year horizon, OCS shares are down 25.8% compared to an 83.0% gain for the broader index. The stock closed at $7.29, standing 62.6% below its 200-day moving average.

Consensus ratings feature 7 Strong Buy, 3 Buy, and 0 Hold or Sell recommendations. The mean analyst price target is $37.00, which is 407.6% above the last close of $7.29. For the current fiscal year ending December 31, 2026, analysts estimate an EPS of -$1.56 on revenue of $878,050. For the next fiscal year, 7 analysts project revenue to reach $4.1M with an estimated EPS of -$1.62. Oculis has beat EPS estimates in 2 of the past 4 quarters, and its next earnings date is scheduled for November 9, 2026.

This page is an AI-written research summary of Oculis Holding AG (OCS). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: OCS income statement, OCS balance sheet, OCS key metrics, OCS analyst forecast, OCS chart. See the OCS stock overview for the latest quote and news.